Independent Research Innovation Award

The Independent Research Innovation Award provides support for the next generation of CF researchers with high-risk,
high-reward ideas that have the potential to significantly impact our understanding of, and approach to, the treatment of cystic fibrosis. The selected research projects must be novel, innovative and, if successful, have the potential for high impact in the field of cystic fibrosis.

Up to 2 grants of $750,000 are available to newly independent researchers conducting an independent research program over 3 years. The program is designed to support clinical and non-clinical research in CF, and applications are welcome from across the spectrum in this field.

Submitting your proposal

Eligibility Criteria

  • Newly independent researchers establishing a career in CF research (basic or clinical)
  • PhD, MD, or equivalent
  • Within 15 years of terminal degree
  • Control own research direction, lab space (as applicable), and funding
  • No more than 1 nationally peer reviewed grant (i.e. R01, CFF, or equivalent)
  • At least 1 grant as principal investigator
  • An established publication record in the field of CF
  • Performing research in the field of CF

All CF RIA awards are selected by an independent steering committee. 

Selection Criteria

A. Quality of proposal

  • Innovation of research
  • Feasibility of research
  • Alignment to the CF RIA program's research focus

B. Ability of principal investigator to deliver the project 

  • Experience and achievements of the research center in the CF therapeutic area
  • Quality and availability of resources 
  • Adherence to ethical principles
  • Design, execution, and monitoring of the research program by the principal investigator
  • Demonstrating a reasonable budget

C. Impact of the project on the understanding or treatment of CF


PrivacyTerms of Use
© 2019 Vertex Pharmaceuticals Incorporated | GL-20-1800008 | 02/2019
Vertex and the Vertex triangle logo are trademarks of Vertex Pharmaceuticals Incorporated 
CF RIA program funding is supported by Vertex Pharmaceuticals Incorporated